- No history of gastrointestinal bleeding (GI) bleeding requiring a blood transfusion, endoscopic or operative intervention
|
-
No history of any prior stroke (hemorrhagic or ischemic)
|
-
No concurrent anticoagulation with warfarin or heparin/heparin analogues, clopidogrel, oral direct thrombin inhibitors, or direct factor XA inhibitors
|
-
No history of atrial fibrillation or myocardial infarction
|
-
No history of grade 4 hypertension, defined as hypertension resulting in life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis)
|
-
No chronic (duration > 30 days) daily use of oral steroids
|
-
No known allergy to aspirin
|
-
No prior malignancy of any type (including ductal breast carcinoma in situ [DCIS]) within the past 5 years except for current diagnosis of breast cancer, and any prior diagnosis of basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. Patients with a prior history of breast cancer greater than 5 years from study screening may participate in this study
|
-
Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use
|